Directory CombiChem Resins Sigma Aldrich
Bioscreening Company Directory

Sigma Aldrich

Sigma Aldrich 3050 Spruce St.
63103 St. Louis
MO United States
Sigma-Aldrich is a leading Life Science and High Technology company. Our chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostic and other high technology manufacturing. Sigma-Aldrich® Corporate Headquarters Image
Sigma-Aldrich operates in 40 countries and has 7,600 employees providing excellent service worldwide.
Sigma-Aldrich is commited to Accelerating Customers' Success through Innovation and Leadership in Life Science, High Technology and Service.
The Story of Sigma-Aldrich

Sigma-Aldrich is the world's largest supplier of research biochemical and organic chemicals. Every day more than one million customers around the globe count on Sigma-Aldrich for quality products delivered on time and as promised.

A trusted leader in life science, high technology and service, the story of Sigma-Aldrich has a rich history of innovation.

Sigma® Chemical Company

The company's roots spring from 1934 in St. Louis, MO, when two brothers, Aaron Fischer and Bernard Fischlowitz, launched a small consulting firm. The two chemical engineers named their partnership Midwest Consultants – parent company of Sigma Chemical Company – and began to help St. Louis businesses produce a variety of specialty products including cosmetics, shoe dressings, and adhesives and inks for cardboard packaging. The firm incorporated in 1935 and hired Dan Broida, another chemical engineer out of Washington University in St. Louis, to manage the company's growing consulting and production businesses.

During World War II, Midwest manufactured ammunition components and made felt and paper parts for signal flares. In addition, saccharin was in high demand and short supply. To fill the need, Broida formed Sigma Chemical Company as a division of Midwest Consultants. For a year, major distributing companies bought saccharin as fast as Sigma could produce it. When the war ended, however, supplies of many raw materials again became plentiful and effectively forced Sigma out of the market.

In its search for a new direction, Sigma's turn toward research biochemicals came in the form of Lou Berger, a friend of Broida who had completed a MS degree in biochemistry at the Washington University in St. Louis School of Medicine under Nobel Laureates Carl and Gerty Cori. As a graduate student, one of Berger's tasks had been to extract adenosine triphosphate (ATP) from rabbit muscle. ATP is a major source of energy in living organisms and was used extensively in the Cori's research. The Coris and other biomedical researchers at this time were involved in studies requiring ATP in quantity. Berger suggested that Sigma produce the compound on a larger scale and taught his process to Sigma personnel. A small ad in a scientific journal brought orders and Broida expanded production. Within two years, Sigma offered eight additional ATP derivatives and raised purity levels.

Sigma entered the next decades with broad expansion into biochemicals and clinical products. In 1964, Sigma London was formed to establish a more active position in the market in Great Britain. Two more foreign subsidiaries were formed – Sigma Israel (1970) and Sigma Munich in West Germany (1974).

Aldrich Chemical Co.

Alfred R. Bader, an Austrian immigrant and chemistry graduate student at Harvard University, entertained the idea of starting a company to sell research chemicals in 1949. Acting on the premise that chemists needed a wider array of research chemicals and better service, Bader and attorney Jack Eisendrath founded Aldrich Chemical Company in Milwaukee, WI, in 1951.

Aldrich offered 1-methyl-3-nitro-1-nitrosofuanidine (MNNG) as it first product, widely used as a methylating reagent. Other products offered in the early '50s include 3-hydroxypyridine, which later became one of Aldrich's best-selling products; ethyl diazoacetate; tetranitomethane; and ethanedithiol. From 1951 to 1954, Bader developed important collaborations through visits to chemical producers in Europe and the UK. The remainder of the 1950s was characterized by rapid growth in sales and in the number of products offered.

Aldrich's Rare Chemical Library (RCL) grew out of the collecting and salvaging of valuable research samples of retiring or deceased academic researchers and from other sources. Large-scale contributions of samples to the library have come from such noteworthy chemists as Henry Gilman, George Wittig, Robert Woodward, and Louis and Mary Fieser. RCL has led to the discovery and commercialization by others of some valuable chemical commodities, e.g., Roundup® (Monsanto Co.), based on lead compounds obtained from the RCL.

SAFC® St. Louis Building ImageThe late '50s and early '60s witnessed the growing importance of custom synthesis and bulk sales at Aldrich. Over the years, these functions evolved into Sigma-Aldrich Fine Chemicals (SAFC), currently one of four strategic business units within Sigma-Aldrich Corporation.

A significant opportunity in the 1970s came when Professor H. C. Brown of Purdue University asked Aldrich to further develop and commercialize the hydroboration technology and organoborane chemistry that he had developed and patented. This led to the establishment of Aldrich-Boranes, Inc., a wholly owned Aldrich subsidiary created to manufacture hydroboration reagents and products. Some of the first compounds manufactured by Aldrich-Boranes were borane-THF, 9-BBN, and borane-methyl sulfide.

Sigma-Aldrich Corporation

When changing trends in chemical research confirmed the synergy to be realized from their complementary product offerings (approximately 40,000 in total at the time), Aldrich Chemical Co. merged with Sigma International, Ltd. to form Sigma-Aldrich Corporation in 1975. With this marriage of broad capabilities and resources, annual double-digit growth would become the standard in the 1980s and 1990s, with significant expansion in facilities, major acquisitions and ventures into new market sectors paving the way into the 21st century.

Sigma-Aldrich's international expansion took off in the 1980s with the opening of subsidiaries in France, Belgium, Japan, Italy, Netherlands and Spain. The acquisition of Biomakor in Israel in 1986 and Fluka in 1989 in Switzerland strengthened this rapid expansion. Sigma-Aldrich continued to increase its international presence greatly during the 1990s, opening 20 offices during that decade either by acquisition or by establishing a subsidiary. In Scandinavia, Sigma-Aldrich acquired four of its dealers, which became Sigma-Aldrich Sweden, Norway, Finland and Denmark. Following the fall of the Berlin Wall, the Company took advantage of the opening of these new markets by opening subsidiaries in Poland, Czech Republic, Hungary and by acquiring a dealer in Russia. Beginning to establish a presence in the area now known as CAPLA (Canada, Asia Pacific and Latin America), Sigma-Aldrich opened offices and distribution warehouses in Australia, followed by India, South Korea, Singapore and Malaysia, as well as Canada, Mexico, Brazil and Argentina in the Americas. This was only the beginning.

From the acquisiton of Supelco in 1993 and Riedel de Haen in 1997, each increasing Sigma-Aldrich's analytical and chromatography capabilities, the Company continued its growth strategy. The year 1999 brought with it the Company's first strategic plan, with Davd Harvey now at the helm as CEO, taking over for Tom Cori. By the next year, Sigma-Aldrich hit the $1 billion in sales milestone, with 6,000 employees in 33 countries – well-known and trusted worldwide.

In 2001, Sigma-Aldrich acquired Isotec, a leader in stable isotope production whose products are used in basic research and the diagnosis of disease. That same year, the Company opened its $55 million Life Science and High Technology Center in St. Louis. In 2004, Ultrafine, a supplier of contract manufacturing services for drug development, and Tetrionics, a producer of high potency and cytotoxic active pharmaceutical ingredients, became a strategic piece of the Company's portfolio. The following year, Sigma-Aldrich underwent its second strageic plan review, announcing the formation of four customer-centric business units and a strong focus on geographic expansion, Internet sales and process improvement to propel the Company to even greater heights. Jai Nagarkatti, former president of Aldrich, then became president and CEO of Sigma-Aldrich.

Sigma-Aldrich acquired JRH Biosciences (now SAFC Biosciences), a major industrial supplier of cell culture products for the pharmaceutical and biotechnology industries, and the Proligo Group, a global supplier of key genomics research tools. Also in 2005, Sigma-Aldrich announced membership in The RNAi Consortium and joined leading institutions including MIT, Harvard, and Eli Lilly to develop and distribute genome-wide shRNA libraries globally.

Sigma-Aldrich once again increased its global reach through the acquisitions of Beijing Superior Chemicals and Instruments Co. in China, Iropharm in Ireland, and Pharmorphix Ltd. in the UK. Other strategic acquistions would soon follow: Epichem Group Ltd. to expand capabilities in materials sciences and semiconductor markets, and Molecular Medicine BioServices to provide large-scale viral manufacturing capabilities.

In 2007, Sigma-Aldrich achieved another significant milestone by exceeding $2 billion in sales, delivering record earnings and further strengthening its leadership in the markets it serves. The strategic plan was proving to be quite successful, paving the way for a renewed focus the following year through the Company's third strategic plan.

More recently, Sigma-Aldrich acquired ChemNavigator in 2009 to provide researchers with industry-leading chemical compound selection and procurement services. That same year, the Company introduced CompoZr™ Zinc Finger Technology and Sigma Advanced Genetic Engineering (SAGE™) Labs to offer next-generation rodent research models that can provide new insight into human disease. Sage Labs' targeted knockout rat ranked among The Scientist magazine's top five innovations of 2009.

In the decades since the 1975 merger, the Company has generated exceptional growth and continues to undergo many positive changes to drive Sigma-Aldrich into the future of science and technology. One such change has been the rise of the Internet and e-commerce, now accounting for approximately 45% of all research sales to become the Company's most powerful marketing tool. In addition, as Sigma-Aldrich continually increases its global reach, approximately 65% of sales stem from outside of the U.S.

Our future success requires more innovative products, faster technologies, and more sophisticated tools that support our customers' success. To accomplish this, our Company has new strategic initiatives that are expected to drive innovation and expand into new markets by leveraging our core scientific strengths: Analytical Chemistry, Biology, and Chemistry-Materials Science (ABCM). Our ABCM initiatives will help us expand our product offering, open new markets and enhance our position in the areas we know best.

Today, Sigma-Aldrich has a broad offering of more than 130,000 chemical products (48,000 of which the Company manufactures) and 40,000 equipment items. We supply products to customers in over 150 countries around the world through state-of-the-art distribution centers. With a committed workforce of approximately 8,000 employees in 38 countries, Sigma-Aldrich has the unrivalled scientific knowledge, unsurpassed service, and global reach to serve researchers and technologists and to ultimately improve quality of life.

Sigma-Aldrich® Worldwide Map Image


Description Accelerate your drug discovery process by validating your assay with proven pharmacologically-active compounds. Improve screening efficiency with the newly expanded version of the Sigma-RBI Library of Pharmacologically Active Compounds. Like its predecessor (LOPAC640™), LOPAC1280™ allows you to validate your high throughput screening assays with high purity, small organic ligands with well documented pharmacological activities. The addition of compounds in areas such as apoptosis and phosphorylation broaden the application range of LOPAC1280™ to assays dealing with the hottest areas of Cell Signaling & Neuroscience research. Save time and money by reducing the number of false leads from your screen. Guide secondary screening of larger, more diverse libraries by using compounds with pharmaceuticallyrelevant structures. Explore the activity of well-characterized compounds directed at orphan receptors.
Additional Info
MyriaScreen Diversity Collection
Description MyriaScreen was created by combining medicinal chemistry expertise and decades of experience in compound acquisition from diverse sources. TimTec’s proprietary software was used to filter a pool of over 300,000 TimTec and Sigma-Aldrich compounds on the basis of diversity. Additional filters were set to consider MW (>225 and <600), cLogP, H-acceptor, H-donors, and rotatable bonds. Medicinal chemistry specialists refined the selection with great personal attention to remove compounds that were overly represented or not well suited for medicinal chemistry follow-up. MyriaScreen is rich in chemotypes and a valuable source of screening compounds for lead discovery.
Additional info

FacebookMySpaceTwitterDiggDeliciousStumbleuponGoogle BookmarksRedditNewsvineTechnoratiLinkedinMixxRSS Feed